People taking tirzepatide (Mounjaro, Zepbound) dropped significantly more pounds than those taking semaglutide (Ozempic, Wegovy), researchers reported July 8 in the journal JAMA Internal Medicine.
For adults with obesity, without diabetes, combining exercise with the glucagon-like peptide-1 receptor agonist (GLP-1 RA), liraglutide, is effective for weight loss, while preserving bone health, according to a study published online June 25 in JAMA Network Open.
We've all seen the ads and read about celebrities who have successfully lost weight using one of the new weight loss medications like Ozempic, Wegovy and Zepbound that have exploded in popularity over the past year.
Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves symptoms in men and women with a common type of heart failure that has had few therapeutic options.
A Cleveland Clinic study shows that bariatric surgery performed in patients with obesity and moderate to severe obstructive sleep apnea is associated with a significantly lower risk of death and major adverse cardiovascular events, compared with patients who did not have the surgery.
